CL2021001624A1 - Composiciones para la reducción de la expresión transgénica específica de drg. - Google Patents
Composiciones para la reducción de la expresión transgénica específica de drg.Info
- Publication number
- CL2021001624A1 CL2021001624A1 CL2021001624A CL2021001624A CL2021001624A1 CL 2021001624 A1 CL2021001624 A1 CL 2021001624A1 CL 2021001624 A CL2021001624 A CL 2021001624A CL 2021001624 A CL2021001624 A CL 2021001624A CL 2021001624 A1 CL2021001624 A1 CL 2021001624A1
- Authority
- CL
- Chile
- Prior art keywords
- drg
- expression
- aav
- compositions
- reduction
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000003594 spinal ganglia Anatomy 0.000 abstract 3
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000012537 formulation buffer Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783956P | 2018-12-21 | 2018-12-21 | |
| US201962924970P | 2019-10-23 | 2019-10-23 | |
| US201962934915P | 2019-11-13 | 2019-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001624A1 true CL2021001624A1 (es) | 2021-11-26 |
Family
ID=71100588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001624A CL2021001624A1 (es) | 2018-12-21 | 2021-06-17 | Composiciones para la reducción de la expresión transgénica específica de drg. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210077553A1 (enExample) |
| EP (1) | EP3908326A4 (enExample) |
| JP (1) | JP7660062B2 (enExample) |
| KR (1) | KR20210107037A (enExample) |
| CN (1) | CN113646005A (enExample) |
| AU (1) | AU2019401314A1 (enExample) |
| BR (1) | BR112021011143A2 (enExample) |
| CA (1) | CA3123600A1 (enExample) |
| CL (1) | CL2021001624A1 (enExample) |
| CO (1) | CO2021008538A2 (enExample) |
| IL (1) | IL284185B2 (enExample) |
| JO (1) | JOP20210160A1 (enExample) |
| MX (1) | MX2021007600A (enExample) |
| PE (1) | PE20211581A1 (enExample) |
| PH (1) | PH12021551341A1 (enExample) |
| SG (1) | SG11202105907QA (enExample) |
| WO (1) | WO2020132455A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021021908A2 (pt) | 2019-05-03 | 2022-02-01 | Univ Pennsylvania | Composições úteis no tratamento da leucodistrofia metacromática |
| WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| CN115803064A (zh) * | 2020-05-12 | 2023-03-14 | 宾夕法尼亚州大学信托人 | 用于drg特异性降低转基因表达的组合物 |
| PE20230767A1 (es) | 2020-05-13 | 2023-05-09 | Voyager Therapeutics Inc | Redireccion del tropismo de las capsides de aav |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| US20230220069A1 (en) | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| EP4179097A1 (en) | 2020-07-13 | 2023-05-17 | The Trustees of The University of Pennsylvania | Compositions useful for treatment of charcot-marie-tooth disease |
| EP4189095A1 (en) | 2020-07-27 | 2023-06-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| KR20230118075A (ko) * | 2020-10-09 | 2023-08-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 파브리병 치료를 위한 조성물 및 방법 |
| US20230383313A1 (en) | 2020-10-18 | 2023-11-30 | The Trustees Of The University Of Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| IL303239A (en) | 2020-12-01 | 2023-07-01 | Univ Pennsylvania | Compositions and their uses for the treatment of Engelmann syndrome |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022198079A1 (en) * | 2021-03-19 | 2022-09-22 | Mayo Foundation For Medical Education And Research | Methods and materials for treating propionic acidemia |
| US20230034817A1 (en) | 2021-04-12 | 2023-02-02 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| AR125406A1 (es) | 2021-04-23 | 2023-07-12 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen |
| WO2022232267A1 (en) | 2021-04-27 | 2022-11-03 | The Trustees Of The University Of Pennsylvania | Porcine-derived adeno-associated virus capsids and uses thereof |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023056399A1 (en) | 2021-10-02 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
| JP2024542950A (ja) * | 2021-10-18 | 2024-11-19 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｃｄｋｌ５欠損症（ｃｄｄ）の治療において有用な組成物 |
| US20250295807A1 (en) * | 2021-11-15 | 2025-09-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| TW202340467A (zh) | 2022-01-10 | 2023-10-16 | 賓州大學委員會 | 有用於治療c9orf72介導之病症之組成物及方法 |
| EP4469585A2 (en) | 2022-01-25 | 2024-12-04 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| KR20250007064A (ko) | 2022-04-06 | 2025-01-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Her2 양성 전이성 유방암 및 기타 암을 치료하기 위한 조성물 및 방법 |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CA3257081A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | VAA CAPSIDE VARIANTS AND THEIR USES |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| EP4543473A1 (en) | 2022-06-22 | 2025-04-30 | Voyager Therapeutics, Inc. | Tau binding compounds |
| CA3259902A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | AAV Capsid Variants and Their Uses |
| TW202424201A (zh) | 2022-07-06 | 2024-06-16 | 美商航海家醫療公司 | Ａａｖ殼體變異體及其用途 |
| AU2023304708A1 (en) * | 2022-07-08 | 2025-01-23 | Consiglio Nazionale Delle Ricerche | Transgene cassettes |
| AU2023320453A1 (en) | 2022-08-03 | 2025-02-06 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| EP4594494A2 (en) * | 2022-09-26 | 2025-08-06 | Encoded Therapeutics, Inc. | Elements for de-targeting gene expression in dorsal root ganglion and/or liver |
| EP4634394A2 (en) | 2022-12-17 | 2025-10-22 | The Trustees of The University of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| KR20250129743A (ko) | 2022-12-29 | 2025-08-29 | 보이저 테라퓨틱스, 인크. | Mapt를 조절하기 위한 조성물 및 방법 |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024228943A1 (en) | 2023-05-02 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| CN121127597A (zh) | 2023-05-03 | 2025-12-12 | 沃雅戈治疗公司 | 用于治疗与葡糖苷酰鞘氨醇酶β1缺陷相关的病症的组合物及方法 |
| WO2024229389A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2024229425A1 (en) | 2023-05-04 | 2024-11-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CN121175424A (zh) * | 2023-05-12 | 2025-12-19 | 上海金珂博生物技术有限公司 | 一种携带smn基因表达框的病毒载体及其用途 |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122644A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025147436A1 (en) | 2024-01-03 | 2025-07-10 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025217023A1 (en) * | 2024-04-08 | 2025-10-16 | The Trustees Of The University Of Pennsylvania | Gene therapy for gangliosidosis type 2 (gm2) |
| WO2025235734A2 (en) | 2024-05-09 | 2025-11-13 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1959012A3 (en) * | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
| SI2002003T1 (sl) * | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| EP1966390A1 (en) * | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| KR101026502B1 (ko) * | 2007-11-23 | 2011-04-01 | 주식회사 파나진 | 마이크로ｒｎａ 안티센스 ｐｎａ, 그를 포함하는 조성물, 및 그의 사용 및 평가 방법 |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP3540055A1 (en) * | 2010-04-23 | 2019-09-18 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| FR3004463A1 (fr) | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| EP3411488A1 (en) * | 2016-02-03 | 2018-12-12 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| JOP20190200A1 (ar) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
-
2019
- 2019-12-20 WO PCT/US2019/067872 patent/WO2020132455A1/en not_active Ceased
- 2019-12-20 CA CA3123600A patent/CA3123600A1/en active Pending
- 2019-12-20 PE PE2021000908A patent/PE20211581A1/es unknown
- 2019-12-20 SG SG11202105907QA patent/SG11202105907QA/en unknown
- 2019-12-20 JP JP2021535718A patent/JP7660062B2/ja active Active
- 2019-12-20 MX MX2021007600A patent/MX2021007600A/es unknown
- 2019-12-20 BR BR112021011143A patent/BR112021011143A2/pt unknown
- 2019-12-20 CN CN201980092720.6A patent/CN113646005A/zh active Pending
- 2019-12-20 JO JOP/2021/0160A patent/JOP20210160A1/ar unknown
- 2019-12-20 KR KR1020217021804A patent/KR20210107037A/ko active Pending
- 2019-12-20 AU AU2019401314A patent/AU2019401314A1/en active Pending
- 2019-12-20 IL IL284185A patent/IL284185B2/en unknown
- 2019-12-20 EP EP19897715.9A patent/EP3908326A4/en active Pending
-
2020
- 2020-11-13 US US17/097,997 patent/US20210077553A1/en active Pending
-
2021
- 2021-06-07 PH PH12021551341A patent/PH12021551341A1/en unknown
- 2021-06-17 CL CL2021001624A patent/CL2021001624A1/es unknown
- 2021-06-29 CO CONC2021/0008538A patent/CO2021008538A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202105907QA (en) | 2021-07-29 |
| JOP20210160A1 (ar) | 2023-01-30 |
| JP7660062B2 (ja) | 2025-04-10 |
| CN113646005A (zh) | 2021-11-12 |
| IL284185B2 (en) | 2025-04-01 |
| BR112021011143A2 (pt) | 2022-01-25 |
| IL284185A (en) | 2021-08-31 |
| EP3908326A4 (en) | 2022-10-26 |
| JP2022517174A (ja) | 2022-03-07 |
| KR20210107037A (ko) | 2021-08-31 |
| CO2021008538A2 (es) | 2021-07-19 |
| MX2021007600A (es) | 2021-08-11 |
| CA3123600A1 (en) | 2020-06-25 |
| US20210077553A1 (en) | 2021-03-18 |
| PH12021551341A1 (en) | 2021-12-13 |
| EP3908326A1 (en) | 2021-11-17 |
| AU2019401314A1 (en) | 2021-06-24 |
| PE20211581A1 (es) | 2021-08-17 |
| IL284185B1 (en) | 2024-12-01 |
| WO2020132455A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001624A1 (es) | Composiciones para la reducción de la expresión transgénica específica de drg. | |
| CL2020001428A1 (es) | Terapia genética para la mucopolisacaridosis iiib. | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
| MX2020008933A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
| CO2022017959A2 (es) | Composiciones para la reducción específica de la expresión transgénica en drg. | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| MX2022015048A (es) | Viriones de virus adenoasociados con variantes de capsides y metodos de uso de estos. | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| AR124736A1 (es) | EFECTO SINÉRGICO DE SMN1 Y miR-23a EN EL TRATAMIENTO DE LA ATROFIA MUSCULAR ESPINAL | |
| ZA202003416B (en) | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies | |
| MX2023012509A (es) | Vectores aavrh74 para la terapia génica de distrofias musculares. | |
| MX2023001137A (es) | Beta-glucocerebrosidasa mutada con estabilidad mejorada. | |
| DOP2024000204A (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia | |
| EA202191744A1 (ru) | Композиции для drg-специфического снижения экспрессии трансгена | |
| CO2024007283A2 (es) | Genoterapia para el tratamiento de la mucopolisacaridosis iii a | |
| MX2021007379A (es) | Metodos y composiciones para el tratamiento de enfermedades de almacenamiento de glucogeno. | |
| EA202192346A1 (ru) | Доставка -саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии | |
| PE20251173A1 (es) | Composiciones y metodos para el tratamiento de la perdida auditiva no relacionada con la edad en un sujeto humano | |
| AR132721A1 (es) | Inhibición de citotoxicidad de las células asesinas naturales (nk) contra terapias celulares | |
| AR111681A1 (es) | Polinucleótidos moduladores |